With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.82019-32-7,7-Bromo-1-methyl-1H-quinoxalin-2-one,as a common compound, the synthetic route is as follows.
Bis(neopentyl glycolato)diboron (1.42 mg, 6.30 mmol) and potassium acetate (823 mg, 8.40 mmol) were added to a solution of 7-bromo-1-methylquinoxalin-2(1H)-one (1.0 g, 4.2 mmol) in 1,4-dioxane (15 mL). The reaction mixture was degassed under nitrogen for 30 min before Pd(dppf)Cl2.DCM (171 mg, 0.21 mmol) was added. The reaction mixture was heated at 80 C. for 3 h. After this time the reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography eluting with 30% EtOAc in iso-hexane to afford an orange solid. Trituration with diethyl ether afforded the title compound as an off-white solid (340 mg, 30%). 1H NMR (400 MHz, CDCl3): delta 8.37-8.30 (m, 1H), 7.79 (m, 3H), 3.82 (s, 4H), 3.75 (s, 3H), 1.06 (s, 6H)., 82019-32-7
The synthetic route of 82019-32-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; ASTRAZENECA AB; LONN, Hans Roland; CONNOLLY, Stephen; SWALLOW, Steven; KARLSSON, Staffan PO; AURELL, Carl-Johan; PONTEN, John Fritiof; DOYLE, Kevin James; VAN DE POEL, Amanda Jane; JONES, Graham Peter; WATSON, David Wyn; MACRITCHIE, Jaqueline Anne; PALMER, Nicholas John; US2015/210655; (2015); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider